What Should Be the Primary Target of “Treat to Target” in Psoriatic Arthritis?

REFERENCES

1. 1.↵
   1. Smolen JS,
   2. Braun J,
   3. Dougados M,
   4. Emery P,
   5. Fitzgerald O,
   6. Helliwell P,
   7. et al.

   Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis 2014;73:6–16.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Coates LC,
   2. Moverley AR,
   3. McParland L,
   4. Brown S,
   5. Navarro-Coy N,
   6. O’Dwyer JL,
   7. et al.

   Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): A UK multicentre, open-label, randomised controlled trial. Lancet 2015;386:2489–98.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Coates LC,
   2. Helliwell PS

   . Defining low disease activity states in psoriatic arthritis using novel composite disease instruments. J Rheumatol 2016;43:371–5.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Schoels MM,
   2. Aletaha D,
   3. Alasti F,
   4. Smolen JS

   . Disease activity in psoriatic arthritis (PsA): Defining remission and treatment success using the DAPSA score. Ann Rheum Dis 2016;75:811–8.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Perrotta FM,
   2. Marchesoni A,
   3. Lubrano E

   . Minimal disease activity and remission in psoriatic arthritis patients treated with anti-TNF-α drugs. J Rheumatol 2016;43:350–5.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Coates LC,
   2. Mahmood F,
   3. Emery P,
   4. Conaghan PG,
   5. Helliwell PS

   . The dynamics of response as measured by multiple composite outcome tools in the tight control of inflammation in early psoriatic arthritis (TICOPA) trial. Ann Rheum Dis 2017;76:1688–92.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Smolen JS,
   2. Schöls M,
   3. Braun J,
   4. Dougados M,
   5. FitzGerald O,
   6. Gladman DD,
   7. et al.

   Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis 2018;77:3–17.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Gladman DD,
   2. Mease PJ,
   3. Strand V,
   4. Healy P,
   5. Helliwell PS,
   6. Fitzgerald O,
   7. et al.

   Consensus on a core set of domains for psoriatic arthritis. J Rheumatol 2007;34:1167–70.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Wells GA,
   2. Boers M,
   3. Shea B,
   4. Brooks PM,
   5. Simon LS,
   6. Strand CV,
   7. et al.

   Minimal disease activity for rheumatoid arthritis: a preliminary definition. J Rheumatol 2005;32:2016–24.

   OpenUrlAbstract/FREE Full Text